AZT: An old drug with new perspectives

Current Clinical Pharmacology

Volumn 3, Issue 1, 2008, Pages 20-37

  D'Andrea, Gabriele ^a   Brisdelli, Fabrizia ^a   Bozzi, Argante ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

AZT; Drug delivery; Glycosylation; HIV; Plant lectins; Plant toxins; Prodrug

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ACETYLCYSTEINE; ALCOHOL; ANTINEOPLASTIC AGENT; CHIMERIC PROTEIN; CHLOROQUINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMIN; HEMOPOIETIC GROWTH FACTOR; IMMUNOMODULATING AGENT; IMMUNOTOXIN; INTERLEUKIN 1; INTERLEUKIN 3; LAMIVUDINE PLUS ZIDOVUDINE; LITHIUM CARBONATE; MULTIDRUG RESISTANCE PROTEIN; N,N DIMETHYLACETAMIDE; OLEIC ACID; PROPYLENE GLYCOL; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HEMOGLOBIN; RETROVIS; RICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAPORIN TRANSFERRIN CONJUGATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ZIDOVUDINE TUFTSIN CONJUGATE; ZINC;

AMINO ACID SEQUENCE; ANEMIA; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BRAIN TUMOR; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL; COLONY FORMING CELL; COLONY FORMING UNIT GM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HEMATOLOGIC MALIGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON OVERLOAD; IRON TRANSPORT; LIPOGENESIS; LOW DRUG DOSE; LYMPHOCYTOPENIA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEOMICS; REVIEW; THROMBOCYTOPENIA;

ADMINISTRATION, CUTANEOUS; ANEMIA; ANIMALS; ANTI-HIV AGENTS; BONE MARROW; ERYTHROID CELLS; GLYCOSYLATION; HUMANS; IMMUNOTOXINS; IRON; P-GLYCOPROTEIN; PRODRUGS; PROTEOMICS; ZIDOVUDINE;

EID: 38949124496     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408783329913     Document Type: Review

References (229)

1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305: 1425-31.
2. Horowitz JP, Chua J, Noel MJ. Nucleoside. V. The monomesylateds of 1-(2′-deoxy-β-D-lyxofuranosyl) thymines. Org Chem Sem Monogr 1964; 29: 2076-8.
3. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 192-7.
4. Kellam P, Boucher CA, Larder BA. Fifth mutations in HIV-1 resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89: 1934-8.
5. Ren J, Esnouf RM, Hopkins AL, et al. 3′-Azido-3′deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long-range conformational changes. Proc Natl Acad Sci USA 1998; 95: 9518-23.
6. Chariot P, Drogou I, De Lacroix-Szmania I, et al. Zidovudine induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30: 156-60.
7. Girard PM, Pegram PS, Diquet B, et al. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr 2000; 23: 227-35.
8. Grootuis DR, Levy RM. The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 1997; 3: 387-400.
9. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-100.
10. Duesberg PH. HIV is not the cause of AIDS. Science 1988; 241: 514-7.
11. Duesberg PH. In: Inventing the AIDS Virus. Washington, USA, Regnery Publishing Inc. 1996.
12. Dyer I, Low JN, Tollin P, Wilson HR, Howie RA. Structure of 3′-Azido-3′-deoxythymidine, AZT. Acta Crystallogr C 1988; 44: 767-9.
13. Wong-Staal F. In: Smith RA Ed, HIV and Other Highly Pathogenic Viruses. San Diego, CA, Academic Press. 1988; 33-41.
14. Haseltine WA. In: Smith RA Ed, HIV and Other Highly Pathogenic Viruses. San Diego, CA, Academic Press. 1988; 25-32.
15. Fischl MM, Richman DD, Grieco MH, et al. The efficacy of azido-thymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-91.
16. Richman DD. The treatment of HIV infection. Azidothymidine (AZT) and other new antiviral drugs. Infect Dis Clin North Am 1988; 2: 397-407.
17. Richman DD, Andrews J. Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. Am J Med 1988; 85: 208-13.
18. Furman PA, Fyfe JA, St. Clair MH, et al. Phosphorylation of 3′- azido-3′-deoxythymidine and selective interaction of the 5′ - triphosphate with the human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333-7.
19. Cheng Y, Dutschman GE, Bastow KF, Sarngadharan MG, Ting RYC. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem 1987; 262: 2187-9.
20. Vrang L, Bazin H, Remaud G, Chattopadhyaya J, Oberg B. Inhibition of the reverse transcriptase from HIV by 3′-azido-3′- deoxythymidine triphosphate and its threo analogue. Antiviral Res 1987; 7: 139-49.
21. St. Clair MH, Richards CA, Spector T, et al. 3′-Azido-3′- deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987; 31: 1972-7.
22. Bazin H, Chattopadhyaya J, Datema R, et al. An analysis of the inhibition of replication of HIV and MuLV by some 3′-blocked pyrimidine analogs. Biochem Pharmacol 1989; 38: 109-19.
23. Sormadossi JP, Carlisle R, Zhou Z. Cellular pharmacology of 3′- azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol 1989; 36: 9-14.
24. Furman PA, Barry DW. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med 1988; 85: 176-81.
25. Parang K, Wiebe LI, Knaus EE. Novel approaches for designing 5′-O-ester prodrugs of 3′-azido-2′, 3′-dideoxythymidine (AZT). Curr Med Chem 2000; 7: 995-1039.
26. Brenner BG, Wainberg MA. The role of antiretrovirals and drug resistance in vertical transmission of HIV-1 infection. Ann N Y Acad Sci 2000; 918: 9-15.
27. Mulato AS, Cherrington JM. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res 1997; 36: 91-7.
28. Buckheit RW, Russell JD, Pallansch LA, Driscoll JS. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2′-fluoro-2′,3′- dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication. Antivir Chem Chemother 1999; 10: 115-9.
29. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1: 575-80.
30. Schmitz SH, Scheding S, Voliotis D, Rasokat H, Diehl V, Schrappe M. Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood. Ann Hematol 1994; 69: 135-8.
31. Kline MW, Van Dyke RB, Lindsey JC, et al. A randomized comparative trial of stavudme (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. Pediatrics 1998; 101: 214-20.
32. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617-22.
33. Chow FP, Hamburger AW. Time-dependent changes induced by azidothymidine in erythroid progenitor colonies in immunodeficient mice. Exp Hematol 1992; 20: 245-50.
34. Lerza R, Castello G, NUla GS, et al. In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3′- azido-3′-deoxy-thymidine, 2′,3′-dideoxycytidine combination. Exp Hematol 1997; 25: 252-5.
35. Gallicchio VS, Hughes NK. Influence of interleukin-3 on zidovudine (AZT)-induced in vitro toxicity to human hematopoietic progenitors. Int J Cell Cloning 1992; 10: 99-104.
36. Gallicchio VS, Hughes NK. Effective modulation of the haematopoietic toxicity associated with zidovudine exposure to murine and human haematopoietic progenitor stem cells in vitro with lithium chloride. J Intern Med 1992; 231: 219-26.
37. Gallicchio VS, Hughes NK, Tse KF, Gaines H. Prevention of the hematopoietic toxicity associated with zidovudine in vivo with IL-1 alone or in combination with GM-CSF administered to normal mice. Growth Factors 1993; 9: 177-83.
38. Gallicchio VS, Hughes NK, Tse KF. Modulation of the haematopoietic toxicity associated with zidovudine in vivo with lithium carbonate. J Intern Med 1993; 233: 259-68.
39. Gallicchio VS, Hughes NK, Tse KF. Prevention of hematopoietic myeloid and megakaryocyte toxicity associated with zidovudine in vivo in mice with recombinant GM-CSF. Growth Regul 1994; 4: 41-7.
40. Gallicchio VS, Hughes NK, Tse KF, et al. Effect of combination interleukin-3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-CSF) on hematopoiesis administered to retrovirus-infected immumodeficient mice receiving dose-escalation zidovudine (AZT). Int J Immunopharmacol 1995; 17: 865-78.
41. Luster MI, Germolec DR, White KL, et al. A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: in vitro toxicity to precursor cells and microstromal environment. Toxicol Appl Pharmacol 1989; 101: 328-39.
42. Castello G, Mela G, Cerruti A, Mencoboni M, Lerza R. Azido-thymidine and interferon-alpha in vitro effects on hematopoiesis: protective in vitro activity of IL-1 and GM-CSF. Exp Hematol 1995; 23: 1367-71.
43. Moqattash S, Lutton JD, Rosenthal G, Abu-Hijleh MY, Abraham NG. Effect of blood substitute recombinant hemoglobin, on in vivo hematopoietic recovery from AZT toxicity. Acta Haematol 1997; 98: 76-82.
44. Gallicchio VS, Hughes NK. Influence of human granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein (PIXY321) on the hematopoietic toxicity associated with anti-viral drugs (zidovudine and didanosine) in vitro using normal human marrow cells. Life Sci 1995; 57: 265-73.
45. Fowler DA, Rosenthal GJ, Sommadossi JP. Effect of recombinant human hemoglobin on human bone marrow progenitor cells: protection and reversal of 3′-azido-3′-deoxythymidine-induced toxicity. Toxicol Lett 1996; 85: 55-62.
46. Gribaldo L, Malerba I, Collotta A, Casati S, Pessina A. Inhibition of CFU-E/BFU-E by 3′-azido-3′-deoxythymidine, chlorpropamide, and protoporphirin IX zinc (II): a comparison between direct exposure of progenitor cells and long-term exposure of bone marrow cultures. Toxicol Sci 2000; 58: 96-101.
47. Lutton JD, Mathew A, Levere RD, Abraham NG. Role of heme metabolism in AZT-induced bone marrow toxicity. Am J Hematol 1990; 35: 1-5.
48. Weidner DA, Sommadossi JP. 3′-Azido-3′-deoxythymidine inhibits globin gene transcription in butyric acid-induced K-562 human leukemia cells. Mol Pharmacol 1990; 38: 797-804.
49. Hobbs GA, Keilbaugh SA, Simpson MV. The Friend murine erythroleukemia cell, a model system for studying the association between bone marrow toxicity induced by 3′-azido-3′-dideoxythymidine and dideoxynuclooside inhibition of mtDNA replication. Biochem. Pharmacol 1992; 43: 1397-400.
50. Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi JP. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992; 51: 668-76.
51. Chitnis S, Mondal D, Agrawal KC. Zidovudine (AZI) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFRα) gene expression in murine bone marrow cells. Life Sci 2002; 71: 967-78.
52. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. Blood 1998; 91: 301-8.
53. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001; 28: 7-14.
54. Groopman JE. Fatigue in cancer and HIV/AIDS. Oncology 1998; 12: 335-44.
55. Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: A main component of anemia symptomatology. Semin Oncol 2001; 28: 15-8.
56. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's interagency HIV study. J Acquir Immune Defic Syndr 2001; 26: 28-35.
57. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999; 13: 943-50.
58. Keiser P, Rademacher S, Smith JW, Skiest D, Vadde V. Granulocyte colony-stimulating factor use is associated with decreased bacteremia, and increased survival in neutropenic HIV-infected patients. Am J Med 1998; 104: 48-55.
59. Gogu SR, Beckman BS, Wilson RB, Agrawal KC. Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3. Biochem Pharmacol 1995; 50: 413-9.
60. Spiga MG, Weidner DA, Trentesaux C, Le Boeuf RD, Sommadossi JP. Inhibition of beta-globin gene expression by 3′-azido-3′-deoxythymidine in human erythroid progenitor cells. Antiviral Res 1999; 44: 167-77.
61. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, Vlahov D, for the Human Immunodeficiency Virus Epidemiology Research Study Group. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002; 34: 260-6.
62. Moyle G. Anaemia in persons with HIV infection: Prognostic marker and contributor to morbidity. AIDS Rev 2002; 4: 13-20.
63. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322: 1488-93.
64. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. J Am Med Assoc 1989; 210: 3104-7.
65. Gogu SR, Malter JS, Agrawal KC. Zidovudine induced blockade of the expression and function of the erythropoietin receptor. Biochem Pharmacol 1992; 44: 1009-12.
66. Nijhof W, Wierenga PK, Sahr K, Beru N, Goldwasser E. Induction of globin mRNA transcription by erythropoietin in differentiating erythroid precursor cells. Exp Hematol 1987; 15: 779-83.
67. Mufson RA, Gesner TG. Binding internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood 1987; 69: 1485-90.
68. Mason-Garcia M, Weill CL, Beckman BS. Rapid activation by erythropoietin of protein kinase C in nuclei of erythroid progenitor cells. Biochem Biophys Res Commun 1990; 168: 490-7.
69. Ottman OG, Ganser A, Seipatt G, Eder M, Schultz G, Hoelzer D. Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood 1990; 76: 1494-502.
70. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T lymphotrophic virus type III:lymphadenopathy-associated virus (HTLV-III:LAV) by 2′,3′-dideoxy-nucleosides. Proc Natl Acad Sci USA 1986; 83: 1911-5.
71. Collier AC, Bozzette S, Coombs RW. A pilot study of low-dose zidovudine in human immunodeficiency virus infectibn. N Engl J Med 1990; 323: 1015-21.
72. Levere RD, Gong Y-F, Kappas A, Bucher DJ, Wormser GP, Abraham NG. Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine. Proc Natl Acad Sci USA 1991; 88: 1756-9.
73. Loewy G, Cook P, Ahmed T, et al. Specificity of heme for hemopoietic recovery from AZT toxicity. Hematol Pathol 1992; 6: 79-85.
74. Fowler DA, Xie M-Y, Sommadossi J-P. Protection and rescue from 2′,3′-dideoxypyrimidine nucleoside analog toxicity by hemin in human bone marrow progenitor cells. Antimicrob Agents Chemother 1996; 31: 191-5.
75. Gogu SR, Agrawal KC. The protective role of zinc and N-acetylcysteine in modulating zidovudine induced hematopoietic toxicity. Life Sci 1996; 59: 1323-9.
76. Weidner DA, Bridges EG, Cretton EM, Sommadossi J-P. Comparative effects of 3′-amino-3′-deoxythymidine on hemoglobin synthesis in K-562 human leukemia cells. Mol Pharmacol 1992; 41: 252-8.
77. Bridges EG, Trentesaux C, Lahlil R, Spiga M-G, Jeannesson P, Sommadossi J-P. 3′-Azido-3′-deoxythymidine inhibits erythroid-specific transcription factors in human erythroid K562 leukemia cells. Eur J Hematol 1996; 56: 62-7.
78. Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992; 102: 879-85.
79. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J Biol Chem 1993; 268: 14991-7.
80. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998; 251: 252-61.
81. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94: 4028-33.
82. Zaman GJR, Cnubben NHP, vanBladeren PJ, Evers R, Borst P. Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEDS Lett 1996; 391: 126-30.
83. Paulusma CC, Bosma PJ, Zaman GJR, et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996; 271: 1126-8.
84. Flens MJ, Zaman GJR, van derValk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996; 148: 1237-47.
85. Evers R, Zaman GJR, vanDeemter L, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996; 97: 1211-8
86. Collington GY, Hunter J, Alien CN, Simmons NL, Hirst BH. Polarized efflux of 2′,7′-bis(2-carboxyethyl)-5(6)-car-boxyfluorescein from cultured epithelial cell monolayers. Biochem Pharmacol 1992; 44: 417-24.
87. Fujita T, Yamada H, Fukuzumi M, Nishimaki A, Yamamoto A, Muranishi S. Calcein is excreted from the intestinal mucosal cell membrane by the active transport system. Life Sci 1997; 60: 307-13.
88. Germann UA, Pastan I, Gottesman MM. P-glycoproteins: mediators of multidrug resistence. Semin Cell Biol 1993; 4: 63-76.
89. Childs S, Ling V. The MDR superfamily of genes and its biological implications. In: De Vita VT, Hellmann S, Rosenberg SA Eds, Important Advances in Oncology. Philadelphia, JB Lippincot Co. 1994; 21-36.
90. Kartner N, Riodan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1058-88.
91. Schinkel AH, Borst P. Multidrug resistence mediated by P-glycoproteins. Semin Cancer Biol 1991; 2: 213-26.
92. Hermans P, Clumeck N. Kaposi's sarcoma in patients infected with human virus (HIV): an overview. Cell Mol Biol 1995; 3: 357-64.
93. Signoretti C, Romagnoli G, Turriziani O, Antonelli G, Dianzani F, Cianfriglia M. Induction of the multidrug-transporter P-glyprotein by AZT treatment in tumor cell lines. J Exp Clin Cancer Res 1997; 16: 19-32.
94. Chaudary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemoterapeutic drugs. J Natl Cancer Inst 1993; 85: 632-9.
95. Dabelsteen E, Clausen H. In: Carbohydrate Pathology. Munksgaard, Copenhagen, 1992.
96. Brockhausen I, Kuhns W. In: Glycoproteins and human disease. Heidelberg, Springer-Verlag, 1997.
97. Neuberger A, Van Deenen LLM. In: Glycoproteins and disease. Amsterdam, Elsevier, 1996.
98. Hall ED, Yan J-P, Melançon P, Kuchta RD. 3′-Azido-3′-deoxythymidine potently inhibits protein glycosylation. J Biol Chem 1994; 269: 14355-8.
99. Yan J-P, Ilsley D, Frohlick C, et al. 3′-Azidothymidine, (Zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells at clinically relevant concentrations. J Biol Chem 1995; 270: 22836-41.
100. Steet R, Melançon P, Kuchta RD. 3′-Azidothymidine potently inhibits the biosynthesis of highly branched N-linked oligosaccharides and poly-N-acetyllactosamine chains in cells. J Biol Chem 2000; 275: 26812-20.
101. Steet R, Alizadeh M, Melançon P, Kuchta RD. 3′-Azidothymidine significantly alters glycosphingolipid synthesis in melanoma cells and decreases the shedding of gangliosides. Glycoconj J 1999; 16: 237-45.
102. D'Andrea G, Lizzi AR, Brisdelli F, D'Alessandro AM, Bozzi A, Oratore A. Protein glycans alteration and a different distribution of some enzymatic activities involved in the glycan processing are found in AZT-treated K562 cells. Mol Cell Biochem 2003; 252: 45-51.
103. Lis H, Sharon N. Lectins as molecules and as tools. Annu Rev Biochem 1986; 55: 33-67.
104. De Santis S, Corriero A, Acone F, et al. Lectin histochemistry on the dorsal epidermis of the Breton dog. Acta Histochem 2003; 105: 73-9.
105. Damjanov I. Biology of disease. Lectin cytochemistry and histochemistry. Lab Invest 1987; 57: 5-17.
106. Beeley JG. Lectin techniques. In: Burdon RH, Knippenberg PH Eds, Glycoprotein and Proteoglycan Techniques. Amsterdam, Elsevier. 1985; 301-64.
107. Walker RA. The use of lectins in histopathology. Pathol Res Pract 1989; 185: 826-35.
108. Spicer SS, Schulte BA. Diversity of cell glycoconjugates shown histochemically: a perspective. J Histochem Cytochem 1992; 40: 1-38.
109. Lizzi AR, D'Alessandro AM, Bozzi A, Cinque B, Oratore A, D'Andrea G. Pattern expression of glycan residues in AZT-treated K562 cells analyzed by lectin cytochemistry. Mol Cell Biochem 2007; 300: 29-37.
110. Zimmerman TP, Mahony WB, Prus KL. 3′-azido-3′- deoxythymidine: an unusual nucleoside analog that permeates the membrane of human erythrocytes and lymphocytes by non-facilitated diffusion. J Biol Chem 1987; 262: 5748-54.
111. Domin BA, Mahony WB, Zimmerman TP. Purine nucleo-base transport in human erythrocytes: reinvestigation with a novel 'inhibitor-stop' assay. J Biol Chem 1988; 263: 9276-84.
112. Balzarini J, Pauwels R, Baba M, et al. The in vitro and in vivo antiretrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-deoxythymidine and 2′,3′-dideoxycithidine are highly dependent on the cell species. Biochem Pharmacol 1988; 37: 897-903.
113. Cheng YC, Dutschman GE, Bastow KF, Sarngadharan MG, Ting RY. Human immunodeficiency virus reverse transcriptase: general properties and its interactions with nucleoside triphosphate analogs. J Biol Chem 1987; 262: 2187-9.
114. Kedar PS, Abbots J, Kovacs T, Lesiak K, Torrence W, Wilson SH. Mechanism of HIV reverse transcriptase. enzyme-primer interaction as revealed through studies of a dNTP analogue, 3′-azidothymidine-5′-triphosphate. Biochemistry 1990; 29: 3603-11.
115. Cretton EM, Xie MY, Bevan RJ, Goudgaon NM, Schinazi RF, Sommadossi JP. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 1991; 39: 258-66.
116. Tornevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlated with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 1995; 49: 829-37.
117. Waquar MA, Evans MJ, Manly KF, Hughes RG, Huberman JA. Effects of 2′,3′-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol 1984; 121: 402-8.
118. Dianzani F, Antonelli G, Turriziani O, et al. Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Res Hum Retrov 1994; 10: 1471-8.
119. Di Vito M, Bozzi A, Ferretti A, et al. Intracellular metabolism of 3′-azido-3′-deoxythymidine (AZT): A Nuclear Magnetic Resonance study on T-lymphoblastoid cell lines with different resistance to AZT. Biochem Pharmacol 1997; 54: 979-90.
120. Nyce J, Leonard S, Canupp D, Schulz S, Wong S. Epigenetic mechanisms of drug resistance: drug-induced DNA hypermothylation and drug resistance. Proc Natl Acad Sci USA 1993; 90: 2960-4.
121. Wu S, Liu X, Solorzano MM, Kwock R, Avramis VI. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. J AIDS Hum Retrovirol 1995; 8: 1-9.
122. Lucarelli M, Palitti M, Carotti D, et al. AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation. FEBS Lett 1996; 396: 323-6.
123. Gill PS, Rarick M, Brynes RK, Causey D, Loureiro C, Levine AM. Azidothymidine associated with bone merrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1987; 107: 502-5.
124. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl Med 1990; 322: 1098-105.
125. Resetar A, Spector T. Glucuronidation of 3′-azido-3′- deoxythymidine: human and rat enzyme specificity. Biochem Pharmacol 1989; 38: 1389-93.
126. Good SS, Koole CS, Crouch R, Johnson RL, Rideout JL, de Miranda P. Isolation and characterization of an ether glucuronide od zidovudine, a major metabolite in monkeys and humans. Drug Metab Dispos 1990; 18: 321-6.
127. Chen MS, Woods KL, Prusoff WH: Molecular basis of the anti-neoplastic activity of 3′-amino-3′-deoxythymidine. Mol Pharmacol 1984; 25: 441-5.
128. Goldin RD, Wilkins M, Dourakis S, Parkin J, Lindley R. Iron overload in multiply transfused patients who are HIV seropositive. J Clin Pathol 1993; 46: 1036-8.
129. Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: mechanism, possible consequences, and proposals for management. Infect Agents Dis 1996; 5: 36-46.
130. Salhi Y, Costagliola D, Rebulla P, et al. Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients. J AIDS Hum Retrovirol 1998; 18: 473-8.
131. Pollack S, Weaver J. Azidothymidine (AZT)-induced siderosis. Am J Hematol 1993; 43: 230-3.
132. Owen D, Kühn LC. Noncoding 3′ sequences of the transferrin receptor gene are required for mRNA regulation by iron. EMBO J 1987; 6: 1287-93.
133. Casey JL, Hentze MW, Koeller DM, et al. Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science 1988; 240: 924-8.
134. Müllner EW, Neupert B, Kühn LC. A specific mRNA binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor mRNA. Cell 1989; 58: 373-82.
135. Kornfeld S, Mellman I. The biogenesis of lysosomes, Ann Rev Cell Biol 1989; 5: 483-525.
136. Young SP, Bomford A. Iterative endocytosis of transferrin by K562 cells. Biochem J 1994; 298: 165-70.
137. Melefors Ö, Hentze MW. Iron regulatory factor - the conductor of cellular iron regulation. Blood Rev 1993; 7: 251-8.
138. Breuer W, Epsztejn S, Cabantchik ZI. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmatic pool of chelatable iron (II). J Biol Chem 1995; 270: 24209-15.
139. Trowbridge IS, Omary MB. Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sci USA 1981; 78: 3039-43.
140. Jandl JH, Katz JH. The plasma-to-cell cycle of transferrin. J Clin Invest 1963; 42: 314-26.
141. Seligman PA, Schleicher RB, Allen RH. Isolation and characterization of the transferrin receptor ftom human placenta. J Biol Chem 1979; 254: 9943-6.
142. Schonhorn JE, Akompong T, Wessling-Resnick M. Mechanism of transferrin receptor down-regulation in K562 cells in response to protein kinase C activation. J Biol Chem 1995; 270: 3698-705.
143. D'Alessandro AM, D'Andrea G, Di Ciccio L, et al. 3′-Azido-3′-deoxythymidine reduces the rate of transferrin receptor endocytosis in K562 cells. Biochim Biophys Acta 1999; 1450: 232-41.
144. D'Alessandro AM, Rinaldi AC, D'Andrea G, et al. Evidences that zidovudine (AZT) could not be directly responsible for iron overload in AZT-treated patients: an in vitro study. Clin Chim Acta 2000; 300: 119-30.
145. Kreitman RJ. Chimeric fusion proteins-pseudomonas exotoxin-based. Curr Opin Invest Drugs 2001; 9: 1282-93.
146. Sausville EA. Use of immunotoxins in the treatment of lymphoma. Cancer J 2000; 6: 135-8.
147. Frankel AE, Neville DM, Bugge TA, Kreitman RJ, Leppla SH. Immunotoxin therapy of hematologie malignancies. Semin Oncol 2003; 30: 545-57.
148. Wu M. Enhancement of immunotoxin activity using chemical and biological reagents. Br J Cancer 1997; 75: 1347-55.
149. Muller O, Traore C, Kouyate B. Clinical efficacy of chloroquine in young children with uncomplicated falciparum malaria -a community-based study in rural Burkina Faso. Trop Med Int Health 2003; 8: 202-3.
150. Marquino W, MacArthur JR, Barat LM, et al. Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru. Am J Trop Med Hyg 2003; 68: 120-3.
151. Barduagni P, Schwartz U, Nyamayaro W, Chauke TL. In vivo testing of the therapeutic efficacy of chloroquine on falciparum malaria infections in Chirundu, Mashonaland West, Zimbabwe. Central Afr J Med 1998; 44: 251-4.
152. Warsame M, Abdillahi A, Duale ON, et al. Therapeutic efficacy of chloroquine and sulfadoxine/pyrimethamine against Plasmodium falciparum infection in Somalia. Bull World Health Organ 2002; 80: 704-8.
153. Casellas P, Bourrie BJ, Gros P, Jansen FK. Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem 1984; 259: 9359-64.
154. Ippoliti R, Ginobbi P, Lendaro E, et al. The effect of monensin and chloroquine on the endocytosis and toxicity of chimeric toxins. Cell Mol Life Sci 1998; 54: 866-75.
155. Huang P, Farquhar D, Plunkett W. Selective action of 2′,3′-didehydro- 2′,3′-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J Biol Chem 1992; 267: 2817-22.
156. Wellner RB, Pless DD, Thompson WL. Characterization of 3′-azido-3′-deoxythymidine inhibition of ricin and pseudomonas exotoxin A toxicity in CHO and Vero cells. J Cell Physiol 1994; 159: 495-505.
157. Brisdelli F, Iorio E, Knijn A, et al. Two-step formation of 1H NMR visible mobile lipids during of paclitaxel-treated K562 cells. Biochem Pharmacol 2003; 65: 271-80.
158. Luzi C, Brisdelli F, Cinque B, Cifone G, Bozzi A. Differential sensitivity to resveratrol-induced apoptosis of human chronic myeloid (K562) and acute lymphoblastic (HSB-2) leukemia cells. Biochem Pharmacol 2004; 68: 2019-30.
159. Kurzrock R, Kloetzer WS, Talpaz M, et al. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood 1987; 70: 233-6.
160. Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-58.
161. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 1995; 15: 5531-41.
162. Riordan FA, Bravery CA, Mengubas K, et al. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of BCR/ABL-positive leukemia cells. Oncogene 1998; 16: 1533-42.
163. Lizzi AR, D'Alessandro AM, Zeolla N, et al. The effect of AZT and chloroquine on the activities of ricin and a saporin-transferrin chimeric toxin. Biochem Pharmacol 2005; 70: 560-9.
164. Thompson WL, Scovill JP, Pace JG. Drugs that show protective effects from ricin toxicity in in vitro protein synthesis assays. Nat Toxins 1995; 3: 369-77.
165. Colombatti M, Bisconti M, Dell'Arciprete L, Gerosa MA, Tridente G. Sensitivity of human glioma cells to cytotoxic heteroconjugates. Int J Cancer 1988; 42: 441-8.
166. Hall WA, Godal A, Juell S, Fodstad O. In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg 1992; 76: 838-44.
167. Ippoliti R, Lendaro E, D'Agostino I, et al. A chimeric saporin-transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity. FASEB J 1995; 9: 1220-5.
168. Citores L, Ferreras JM, Munoz R, Benitez J, Jimenez P, Girbes T. Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin 1. Cancer Lett 2002; 184: 29-35.
169. Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 1994; 80: 520-6.
170. Laske DW, Youle R, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997; 3: 1362-8.
171. Gosselaar PH, van-Dijk AJ, de-Gast GC, et al. Tranferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation. Eur J Clin Invest 2002; 32(Suppl 1): 61-9.
172. Colombatti M, Dosio F. Synthesis of monensin derivatives and their effect on the activity of ricin A-chain immunotoxins. Meth Mol Biol 2001; 166: 55-70.
173. Jeffries DJ. The antiviral activity of dideoxycytidine. J Antimicrob Chemother (Suppl A) 1989; 23: 29-34.
174. Hasoun EA, Stohs SJ. Potential chemoprotectant activity of 3′-azido-3′-deoxythymidine (AZT) and 2′,3′-dideoxycytidine (DDC) against ricin toxicity in Chinese hamster ovary and macrophage J774A.1 cell cultures. J Appl Toxicol 1996; 16: 43-8.
175. Steiner S, Witzmann FA. Proteomics: applications and opportunities in preclinical drug development. Electrophoresis 2000; 21: 2099-104.
176. Anderson NL, Esquer-Blasco R, Richardson F, Foxworthy P, Eacho P. The effects of peroxisome proliferators on protein abundance-in mouse liver. Toxicol Appl Pharmacol 1996; 137: 75-89.
177. Eberini I, Miller I, Zancan V, et al. Proteins of rat serum IV. Time course of acute-phase proiein expression and its modulation by in domethacine. Electrophoresis 1999; 20: 846-53.
178. Aicher L, Wahl D, Arce A, Grenet O, Steiner S. New insights into cyclosporine A nephrotoxicity by proteome analysis. Electrophoresis 1998; 19: 1998-2003.
179. Kennedy S. Proteomic profiling from human samples: the body fluid alternative. Toxicol Lett 2001; 120: 379-84.
180. Hampel DJ, Sansome C, Sha M, Brodsky S, Lawson WE, Goligorsky MS. Toward proteomics in uroscopy: urinary protein profiles and radiocontrast medium administration. J Am Soc Nephrol 2001; 12: 1026-35.
181. Yamaguchi T, Katoh I, Kurata SI. Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitization. Eur J Biochem 2002; 269: 2782-8.
182. Collier AC, Helliwell RJ, Keelan JA, Paxton JW, Mitchell MD, Tingle MD. 3′-azido-3′-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta. Toxicol Appl Pharmacol 2003; 192: 164-73.
183. Komarov AM, Hall JM, Weglicki WB. Azidothymidine promotes free radical generation by activated macrophages and hydrogen peroxide-iron-mediated oxidation in a cell-ftee system. Biochim Biophys Acta 2004; 1688: 257-64.
184. Olivero OA, Tejera AM, Fernandez JJ, et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 2005; 20: 139-46.
185. Kurokawa M, Ghooh SK, Ramos JC, et al. Azidothymidine inhibits NF-kB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 2005; 106: 235-40.
186. Carnicelli V, Di Giulio A, Bozzi A, Strom R, Oratore A. Zidovudine inhibits protein kinase C activity in human chronic myeloid (K562) cells. Basic Clin Pharmacol Toxicol 2006; 99: 317-22.
187. Marty R, Ouameur AA, Neault JF, Nafisi S, Tajmir-Riahi HA. AZT DNA interaction. DNA Cell Biol 2004; 23: 135-40.
188. Iwamoto T, Hiraku Y, Oikawa S, Mizatani H, Kojima M, Kawanishi S. Oxidative DNA damage induced by photodegradation products of 3′-azido-3′-deoxythymidine. Arch Biochem Biophys 2003; 416: 155-63.
189. Slamenova D, Horvathova, E, Bartkova M. Nature of DNA lesions induced in human hepatoma cells, human colonic cells and human embryonic lung fibroblasts by the antiretroviral drug 3′-azido-3′-deoxythymidine. Mutat Res 2006; 593: 97-107.
190. De la Asuncion JG, Del Olmo MI, Gomez-Cambronero LG, Sastre J, Pallardo FV, Vina J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci 2004; 76: 47-56.
191. Ji HJ, Rha SY, Jeung HC, Yangm SH, An SW, Chung HC. Cyclic induction of senescence with intermittent AZT treatment accelerates both apootosis and telomere loss. Breast Cancer Res Treat 2005; 93: 227-36.
192. Pan G, Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses 2004; 20: 608-20.
193. Freyssenet D, Di Carlo M, Escobar P, Grey J, Schneider J, Hood DA. Zidovudine (AZT) induced alterations in mitochondrial biogenesis in rat striated muscles. Can J Physiol Pharmacol 1999; 77: 29-35.
194. D'Andrea G, Lizzi AR, Venditti S, et al. Proteins pattern alteration in AZT-treated K562 cells detected by two-dimensional gel electrophoresis and peptide mass fingerprinting. Proteome Sci 2006; 4: 1-7.
195. Fischl MA, Richman DD, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 192-7.
196. De Clercq E. Perspectives for the chemotherapy of AIDS. Anticancer Res 1987; 7: 1023-38.
197. Dessolin J, Gales P, Vlieghe P, Chermann J-C, Kraus J-L. New bicyclam-AZT conjugates: Design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor. J Med Chem 1999; 42: 229-41.
198. Aggarwal SK, Gogu SR, Rangan SRS, Agrawal KC. Synthesis and biological evaluation of zidovudine. J Med Chem 1990; 33: 1505-10.
199. Sharma AP, Ollapally AP, Lee HJ. Synthesis and anti-HIV activity of prodrugs of azidothymidine. Antiviral Chem Chemother 1993; 4: 93-6.
200. Meier C, Knispel T, De Clercq E, Balzarini J. CycloSal-pronucleotides of 2′,3′-dideoxyadenosine and 2′,3′-dideoxy-2′,3′-didehydroadenosine: Synthesis and antiviral evaluation of a highly efficient nucleotide delivery system. J Med Chem 1999; 42: 1604-14.
201. Hong CI, Nechaev A, Kirisits AJ, et al. Nucleoside conjugates. 15. Synthesis and biological activity of anti-HIV nucleoside conjugates of ether and thioether phospholipids. J Med Chem 1996; 39: 1771-7.
202. Namane A, Gouyette C, Fillion M-P, Fillion G, Huynh-Dinh T. Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J Med Chem 1992; 35: 3039-44.
203. Vlieghe P, Clerc T, Pannecouque C, et al. New 3′-Azido-3′-deoxythymidin-5′-yl O-(4-hydroxyalkyl or -alkenyl or -alkylepoxide) carbonate prodrugs: Synthesis and anti-HIV evaluation. J Med Chem 2001; 44: 3014-21.
204. Lee W, Soliman MRI. Anti-inflammatory steroids without pituitary-adrenal suppression. Science 1982; 215: 989-91.
205. Rosner W. Plasma steroid-binding proteins. Endocrinol Metab Clin North Am 1991; 20: 697-720.
206. Matsumoto H, Hamawaki T, Ota H, et al. "Double-drugs" - A new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker. Bioorg Med Chem Lett 2000; 10: 1227-31.
207. Fridkin M, Tsubery H, Tzehoval E, et al. Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy. J Pept Sci 2005; 11: 37-44.
208. Kieburtz KD, Seidlin M, Lambert JS, Dolin R, Reichman R, Valentine F. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J Acquir Immune Defic Syndr 1992; 5: 604.
209. Klecker Jr RW, Coflins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407-12.
210. Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 1999; 43: 603-8.
211. Mollgaard B, Hoelgaard A. Vehicle effect on topical drug delivery. II. Concurrent skin transport of drugs and vehicle components. Acta Pharm Suec 1983; 20: 443-50.
212. Aungst BJ, Blake JA, Hussain MA. Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines. Pharm Res 1990; 7: 712-8.
213. Cho YJ, Choi H-K. Enhancement of percutaneous absorption of ketoprofen: effect of vehicles and adhesive matrix. Int J Pharm 1998; 169: 95-104.
214. Kim J, Cho Y, Choi H. Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin. Int J Pharm 2000; 196: 105-13.
215. Panchagnula R, Salve PS, Thomas NS, Jain AK, Ramarao P. Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin. Int J Pharm 2001; 219: 95-105.
216. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 1960; 11: 85-97.
217. Poulsen BJ. Diffusion of drugs from topical vehicles: an analysis of vehicle effects. Adv Biol Skin 1972; 12: 495-509.
218. Chandrasekaran SK, Shaw JE. Factors influencing the percutaneous absorption of drugs. Curr Probl Dermatol 1978; 7: 142-55.
219. Barry BW. Mode of action of penetration enhancers in human skin. J Control Release 1987; 6: 85-97.
220. Rowe ES. Thermodynamic reversibility of phase transition. Specific effects of alcohols on phosphatidylcholines. Biochim Biophys Acta 1985; 813: 321-30.
221. Ghanem AH, Rohr U, Higuchi WI, et al. The effect of ethanol on the transport of B-estradiol and other permeants in hairless mouse skin. II. A new quantitative approach. J Control Release 1987; 6: 75-83.
222. Kurihara-Bergstrom T, Knutson K, DeNoble LJ, Goates CY. Percutaneous absorption enhancement of an ionic molecule by ethanol-water systems in human skin. Pharm Res 1990; 7: 762-6.
223. Bommannan D, Potts RO, Guy RH. Examination of the effect of ethanol on human stratum corneum in vivo using infrared spectroscopy. J Control Release 1991; 16: 299-304.
224. Kim YH, Ghanem AH, Mahmoud H, Higuchi WI. Short chain alkanols as transport enhancers for lipophilic and polar/ionic permeants in hairless mouse skin: mechanism(s) of action. Int J Pharm 1992; 80: 17-31.
225. Seki T, Toeda C, Kawaguchi T, Juni K, Sugibayashi K, Morimoto Y. Enhanced transdermal delivery of zidovudine in rats and human skin. Chem Pharm Bull 1990; 38: 3086-9.
226. Jin Y, Toeda C, Kawaguchi T, Seki T, Juni K. Permeation of zidovudine and probenecid from oily bases containing alcohols through rat skin. Drug Dev Ind Pharm 1996; 22: 653-8.
227. Kim DD, Chien YW. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J Pharm Sci 1996; 85: 214-9.
228. Panchagnula R, Patel JR. Transdermal delivery of azidothymidine (AZT) through rat skin ex-vivo. Pharm Sci 1997; 3: 83-7.
229. Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006; 14: 45-53.